Zinc, Copper, And Ceruloplasmin: The Balance Most People Are Getting Wrong

Ceruloplasmin in the brain is different from ceruloplasmin in blood.

In the CNS, astrocytes express a GPI-anchored form of ceruloplasmin (GPI-Cp) on their cell surface.

This membrane-bound form is the primary ferroxidase in the brain, and it is absolutely essential for iron homeostasis in the CNS. R

GPI-Cp on astrocytes oxidizes ferrous iron exported from neurons via ferroportin, loads it onto transferrin, and recycles it back to neurons via the transferrin receptor.

Without functional GPI-Cp, ferrous iron accumulates in astrocytes, causing lipid peroxidation and oxidative damage to the very cells that are supposed to support and protect neurons. R

This mechanism explains why aceruloplasminemia causes neurodegeneration despite being a disorder of copper and ceruloplasmin: the failure is ultimately an iron accumulation problem in the brain. R

Ceruloplasmin is also a positive acute-phase reactant, meaning it rises with inflammation, infection, pregnancy, estrogen use, and malignancy.

This is clinically important: inflammation can normalize a low ceruloplasmin, masking underlying copper deficiency and creating a false-negative result. R

Always interpret ceruloplasmin in context of inflammatory markers and serum copper together.

---

How Zinc Depletes Copper: The Metallothionein Mechanism

This is the mechanism behind dozens of documented clinical cases of copper deficiency from zinc supplementation, and it is almost certainly happening at a subclinical level in a much larger population of supplement users.

Metallothionein (MT) is a small cysteine-rich intracellular protein in enterocytes (intestinal absorptive cells) that binds trace metals. R

When zinc intake is elevated, enterocytes increase metallothionein synthesis as a homeostatic response, because MT sequesters excess zinc and prevents its absorption. R

The problem: metallothionein has a much higher binding affinity for copper than for zinc.

When dietary copper arrives in the gut in the presence of elevated metallothionein, the copper binds to metallothionein before zinc does.

Copper-bound metallothionein is trapped inside the enterocyte.

As the enterocyte naturally undergoes cell turnover and is shed into the intestinal lumen (normal process, every 3-5 days), the copper bound to metallothionein is lost in the feces rather than being absorbed into the bloodstream. R

Systemic copper absorption falls. Over weeks to months, serum copper and ceruloplasmin decline.

This mechanism explains several critically important clinical observations:

1. The clinical manifestations of zinc excess are actually the manifestations of copper deficiency: anemia, neutropenia, and myelopathy.
2. Even normal-appearing serum zinc levels can indicate ongoing copper depletion, because the excess zinc that drove up metallothionein may have already been excreted but the metallothionein production is still suppressing copper absorption.
3. In documented cases, stopping zinc supplements and starting oral copper fails to correct the copper deficiency until excess zinc is eliminated from the body, because elevated metallothionein continues to block copper absorption as long as zinc excess persists. R
4. In some cases, intravenous copper was required to bypass the blocked gut absorption entirely. R

How much zinc is too much?

Intake above 40mg/day regularly is considered the threshold for concern. R

Many common OTC supplements contain 25-50mg of zinc per dose.

Long-term use at these doses without copper co-supplementation is a real clinical risk.

Zinc-containing denture adhesives have caused copper deficiency and myelopathy from dermal absorption of zinc, in patients who used them heavily for years. R

The ratio to aim for in supplementation: Most practitioners use a zinc:copper ratio of approximately 8-15:1 (by dose in mg) when supplementing both.

If supplementing 15mg of zinc daily, approximately 1-2mg of copper daily is appropriate to maintain balance.

---

Conditions Linked To Zinc-Copper Imbalance

Zinc Excess / Copper Deficiency

Copper deficiency myelopathy is the most severe neurological consequence of zinc-induced copper depletion.

It presents as a progressive myelopathy (spinal cord disease) with spastic gait, sensory ataxia, and absent or diminished deep tendon reflexes with Babinski signs, closely mimicking subacute combined degeneration from vitamin B12 deficiency. R

Vitamin B12 and copper deficiency can coexist and should always be tested together when either is suspected. R

Sideroblastic anemia and neutropenia are the most common hematological presentations.

The anemia is iron-unresponsive (a critical diagnostic clue), because copper deficiency impairs iron absorption from the gut and iron release from the reticuloendothelial system.

Bone marrow biopsy shows ringed sideroblasts and vacuolization of erythroid and myeloid precursors, which can be misdiagnosed as myelodysplastic syndrome (MDS). R

Unlike MDS, copper deficiency-related marrow changes are fully reversible with copper restoration.

Low testosterone can occur with long-term zinc-induced copper depletion if it impairs cytochrome c oxidase and dopamine-beta-hydroxylase function, affecting adrenergic signaling pathways relevant to testosterone synthesis. Paradoxically, zinc deficiency also causes low testosterone through a different mechanism (low aromatase inhibition).

Dysbiosis is both a cause and consequence of trace mineral imbalance. Gut pathogens and SIBO alter zinc and copper absorption independently of supplementation.

Copper Excess / Aceruloplasminemia

Aceruloplasminemia is a rare autosomal recessive disorder caused by loss-of-function mutations in the ceruloplasmin gene, resulting in complete absence of ceruloplasmin ferroxidase activity. R

Despite being a copper-containing protein disorder, the clinical syndrome is primarily one of iron accumulation, not copper toxicity.

Massive iron deposition occurs in the brain (basal ganglia, dentate nuclei, thalamus, cortex), liver, pancreas, and retina. R

Onset is typically in the 4th-5th decade with:

• Blepharospasm, orolingual dystonia, chorea, dysarthria, ataxia
• Parkinsonism
• Cognitive decline and dementia
• Diabetes mellitus (pancreatic iron deposition damages beta cells)
• Retinal pigmentary degeneration
• Microcytic anemia with paradoxically high ferritin and low transferrin saturation

On MRI, aceruloplasminemia shows the most extreme T2 hypointensity (iron signal) in the basal ganglia of any condition, surpassing Wilson disease. R

Wilson Disease is the mirror image disorder: an autosomal recessive defect in ATP7B, the copper transporter in hepatocyte trans-Golgi network.

ATP7B normally incorporates copper into apoceruloplasmin to form holoceruloplasmin, and mediates biliary excretion of excess copper. R

In Wilson disease, ATP7B dysfunction means copper cannot be incorporated into ceruloplasmin and cannot be excreted into bile.

Free (non-ceruloplasmin-bound) copper accumulates and is toxic.

Serum ceruloplasmin is typically low in Wilson disease because non-coppered apoceruloplasmin is unstable and rapidly degraded. R

Paradoxically, treatment of Wilson disease includes zinc supplementation to induce metallothionein in the gut and block copper absorption, the exact same mechanism that causes copper deficiency in otherwise healthy supplement users. R

Neurodegeneration and Alzheimer's/Parkinson's connection: Ceruloplasmin ferroxidase activity is reduced in the CSF of Parkinson's disease patients. Ceruloplasmin levels are reduced in the cortex in Alzheimer's disease. R

Both diseases are associated with iron accumulation in the substantia nigra (Parkinson's) and amyloid plaques (Alzheimer's).

Impaired ceruloplasmin ferroxidase activity may contribute to neurodegenerative iron accumulation in both conditions.

Mast cell activation is influenced by copper status. Histamine N-methyltransferase (HNMT), which degrades histamine, is a methylation enzyme affected by copper status. Copper-dependent enzymes are also involved in catecholamine synthesis that modulates mast cell reactivity.

---

How To Balance Zinc And Copper

1. Assess Before Supplementing

Test serum copper, serum zinc, and serum ceruloplasmin together before beginning any supplementation protocol.

Serum copper and ceruloplasmin must be interpreted together: ceruloplasmin carries most plasma copper, so low ceruloplasmin almost always means low functional copper (with the caveat that inflammation can normalize ceruloplasmin even when copper is depleted).

If ceruloplasmin is low but the inflammatory picture is unclear, requesting a serum copper alongside it clarifies whether the low ceruloplasmin reflects genuine copper deficiency or is being masked by inflammation.

2. Correct Copper Deficiency First

If copper is low and zinc is elevated, the priority is reducing zinc intake and restoring copper.

Copper Glycinate or Copper Bisglycinate at 1-3mg/day is appropriate for mild to moderate deficiency in a patient who can absorb oral supplements.

If GI absorption is compromised (malabsorption, bariatric surgery, or elevated metallothionein blocking absorption), IV copper may be required to bypass the gut. R

Do not supplement copper aggressively in isolation without testing, as copper excess (Wilson disease phenotype without the genetic defect) is possible and damaging.

3. Supplement Zinc With A Co-Administered Ratio

When zinc supplementation is indicated (infection, wound healing, testosterone support, immune function, taste disturbances), always include copper at approximately 1mg of copper per 10-15mg of zinc.

Zinc Glycinate or Zinc Bisglycinate are the best-absorbed forms with the least GI side effects.

Zinc + Copper Combined Supplement products are available and simplify compliance.

Zinc picolinate and zinc citrate are also well-absorbed.

Zinc oxide (common in cheaper supplements) has significantly lower bioavailability.

4. Support Ceruloplasmin Production

Ceruloplasmin is synthesized in the liver and requires both adequate copper status and functional hepatic biosynthesis.

Liver health is a prerequisite for normal ceruloplasmin levels. Milk thistle (silymarin) and TUDCA support hepatic function relevant to ceruloplasmin synthesis.

Ceruloplasmin synthesis also requires adequate vitamin A (retinol form), as retinol modulates copper metabolism in the liver.

Vitamin C enhances ferroxidase function and may support ceruloplasmin activity indirectly.

5. Dietary Copper From Food

Prioritizing copper-rich foods is the most sustainable approach for most people.

Beef liver 1-2 times per week provides substantial copper in a highly bioavailable form.

Oysters provide both zinc and copper at meaningful amounts.

Dark chocolate (high cocoa) and cashews are practical everyday copper sources.

6. Address Absorption Factors

Dysbiosis reduces copper absorption through multiple pathways including altered gut pH, impaired enterocyte function, and competitive binding by gut organisms.

Malabsorptive GI surgery (Roux-en-Y gastric bypass has a 9-10% prevalence of post-operative copper deficiency) is a major risk factor that requires ongoing monitoring. R

Celiac disease and other causes of villous atrophy significantly reduce copper absorption.

---

What To Stay Away From

• High-dose zinc without copper co-administration (anything above 25mg/day of zinc without 1-2mg of copper coadministered is creating a depletion risk over time; the clinical literature documents copper deficiency from this pattern)
• Zinc-containing denture adhesives used chronically (dermal zinc absorption from heavy denture adhesive use has caused copper deficiency myelopathy; report this to dental patients explicitly) R
• Interpreting ceruloplasmin in isolation (ceruloplasmin is an acute-phase reactant; it rises with inflammation, oral contraceptive use, pregnancy, and valproate use, potentially masking true copper deficiency; always pair it with serum copper and inflammatory markers like CRP or ferritin) R
• Iron supplementation without ruling out ceruloplasmin deficiency (iron therapy will not correct the anemia of copper deficiency; treating with iron when the underlying issue is copper deficiency delays correct diagnosis and exposes the patient to excess iron without benefit)
• Copper supplementation in Wilson disease (copper accumulation is the disease; supplementing copper in an undiagnosed Wilson disease patient is directly harmful)
• Long-term high-dose zinc during active infection or post-COVID recovery (zinc supplementation surged post-COVID and many patients continued high doses indefinitely without copper monitoring; this is a copper deficiency incubation period)
• Mega-dose zinc lozenges for extended cold management (total daily zinc from lozenges can easily exceed 100mg/day; this is effective short-term for cold duration but should not be continued for more than 5-7 days without copper co-supplementation)
• Neglecting copper status in vegetarians and vegans (plant-based diets are lower in bioavailable copper than meat-based diets; compound this with common zinc supplementation in this demographic and the depletion risk is significant)

---

Testing

First-Line Testing

Serum Zinc and Serum Copper should always be ordered together when evaluating either mineral. Individual results without the paired measurement are clinically incomplete.

Serum Ceruloplasmin should be ordered simultaneously.

Reference ranges (approximate):

• Serum copper: 0.75-1.45 mcg/mL (75-145 mcg/dL)
• Serum ceruloplasmin: 20-40 mg/dL
• Serum zinc: 0.66-1.0 mcg/mL

Copper less than 7.9 mcmol/L is considered severe deficiency warranting specialist referral. R

The Nutrient Zoomer from Vibrant Wellness includes serum copper, zinc, and ceruloplasmin as part of its comprehensive micronutrient panel, alongside the vitamins and minerals that context these results.

Individual markers are also available separately: Copper and Zinc via Fullscript Quest Diagnostics.

Second-Line Testing

CBC with Differential: look for anemia and neutropenia as the hematological signature of copper deficiency.

Anemia that is unresponsive to iron therapy and is accompanied by neutropenia should prompt immediate copper evaluation.

24-hour urine copper excretion is useful when Wilson disease (copper excess) or non-ceruloplasmin-bound copper accumulation is suspected. Elevated in active Wilson disease, reduced in copper deficiency.

Iron studies Foundation Zoomer: ferritin, transferrin saturation, serum iron, and TIBC to assess functional iron status alongside the copper-ceruloplasmin picture.

The paradox of high ferritin with low transferrin saturation and anemia (the aceruloplasminemia pattern) should trigger ceruloplasmin testing.

Neurological Evaluation

When copper deficiency myelopathy is suspected, MRI of the cervical and thoracic spinal cord shows T2 hyperintensity in the dorsal columns, identical in appearance to subacute combined degeneration from B12 deficiency. R

The Neural Zoomer from Vibrant Wellness assesses autoantibodies and markers of neuroinflammation relevant to patients with neurological symptoms from trace mineral dysregulation.

---

Mechanisms Of Action

Simple:

• Zinc and copper compete for the same binding protein (metallothionein) in gut cells; when zinc is high, metallothionein preferentially grabs copper and carries it out of the body when the gut cell is shed.
• Copper is required to build ceruloplasmin, the protein that converts toxic ferrous iron (Fe2+) into the safe ferric form (Fe3+) that can ride on transferrin and get where it needs to go.
• Without ceruloplasmin, iron cannot leave cells via the ferroportin transporter, so iron builds up inside cells even while blood levels suggest iron deficiency.
• In the brain, astrocytes use a surface form of ceruloplasmin to recycle iron between themselves and neurons; when this breaks down, iron accumulates in astrocytes, causing oxidative damage that destroys neuronal support.
• Cu/Zn-SOD1 requires both copper AND zinc to function; the copper center does the dismutation chemistry; the zinc center holds the protein in the right shape. Lose either and your primary cytosolic antioxidant enzyme fails.

Advanced:

• Metallothionein induction cascade: Zinc enters the enterocyte via ZIP4 (SLC39A4), elevating intracellular Zn2+. This activates MTF-1 (metal-responsive transcription factor-1), which binds metal response elements (MREs) in the metallothionein promoter and drives MT1 and MT2 expression. The resulting MT proteins have 20 cysteine residues that bind up to 7 zinc atoms or a mixture of metals. MT's binding affinity for Cu is approximately 100-fold greater than for Zn (MT Kd for Cu ~10^-18M vs Kd for Zn ~10^-12M). Dietary copper entering the enterocyte is immediately sequestered by Cu-preferring MT binding sites, preventing transfer to the basolateral copper transporter CTR1 that would export copper to portal circulation. R
• Ceruloplasmin copper incorporation: Holoceruloplasmin is synthesized exclusively in hepatocytes. In the trans-Golgi network, ATP7B transports copper from the cytoplasm to the lumenal side of the Golgi, where the copper chaperone ATOX1 delivers it to ATP7B, which then loads it into nascent apoceruloplasmin via sequential metalation of its six copper-binding sites. Without ATP7B function (Wilson disease), apoceruloplasmin cannot be metalated and is rapidly degraded, explaining the low ceruloplasmin in Wilson disease despite excess hepatic copper. R
• Iron efflux and ferroxidase coupling: Iron stored inside macrophages, hepatocytes, and enterocytes exits via ferroportin (FPN1/SLC40A1), which specifically transports ferrous iron (Fe2+). At the cell surface, membrane-bound ceruloplasmin (GPI-Cp in astrocytes, soluble Cp in hepatocytes) immediately oxidizes Fe2+ to Fe3+. Only Fe3+ can bind to transferrin (TF) via its iron-binding lobes. This oxidation step is the rate-limiting bottleneck for iron mobilization and systemic delivery. Without ceruloplasmin activity, ferrous iron exits ferroportin but cannot be loaded onto transferrin, stalling in the interstitium. Hepcidin then upregulates in response to the apparent iron excess, induces ferroportin internalization and degradation, and traps even more iron intracellularly. This explains the low-transferrin-saturation, high-ferritin presentation of aceruloplasminemia. R
• Cu/Zn-SOD1 (SOD1) mechanism: SOD1 is a 32kDa homodimer with one copper and one zinc per subunit. The copper ion cycles between Cu2+ and Cu+ during catalysis: Cu2+-SOD + O2- → Cu+-SOD + O2 (copper reduced), then Cu+-SOD + O2- + 2H+ → Cu2+-SOD + H2O2 (copper re-oxidized, superoxide reduced to H2O2). Zinc does not participate in this redox cycle; it stabilizes the protein's Greek key beta-barrel structure and maintains the shape of the active site for copper positioning. CCS (copper chaperone for SOD1) specifically delivers copper to nascent SOD1 and also forms the disulfide bond that locks the active conformation. Loss of either copper or zinc impairs SOD1 function, reducing cytosolic superoxide dismutation. R
• Aceruloplasminemia iron-astrocyte-neuron cycle disruption: In normal brain, astrocytes export Fe3+ bound to transferrin across the interstitium to neurons, where TfR1 (transferrin receptor 1) internalizes the Fe3+-transferrin complex. GPI-Cp on the astrocyte surface is required to oxidize intracellular Fe2+ (exported from astrocytes via ferroportin) to Fe3+ for loading onto transferrin. In aceruloplasminemia, Fe2+ exits astrocytes via ferroportin but cannot be oxidized, so it fails to bind transferrin and instead accumulates in the astrocyte interstitium and cytoplasm. The non-transferrin-bound iron (NTBI) undergoes Fenton chemistry (Fe2+ + H2O2 → Fe3+ + OH• + OH-), generating the most potent reactive oxygen species in biology. Astrocytes, overwhelmed by oxidative damage, lose their capacity to support neurons. Neurons, starved of transferrin-bound iron, eventually begin taking up NTBI via alternative pathways that further increase their oxidative burden. R

---

Genetics

ATP7B (Wilson Disease)

ATP7B encodes the ATPase copper transporter ATP7B on chromosome 13q14.3.

ATP7B is expressed primarily in hepatocytes and functions in the trans-Golgi network to incorporate copper into ceruloplasmin and to traffic excess copper to the canalicular membrane for biliary excretion.

Over 300 pathogenic variants have been described; most patients are compound heterozygotes (two different mutations). R

The most common European variant is H1069Q (His1069Gln). The R778L variant predominates in Asian populations.

Wilson disease has a prevalence of approximately 1 in 30,000, but the genetic carrier frequency indicates the disease is substantially underdiagnosed. R

Phenotype is highly variable: liver disease (hepatitis, cirrhosis), neurological disease (tremor, dysarthria, ataxia, dystonia), psychiatric disease (personality change, psychosis), or a combination.

Kayser-Fleischer rings (copper deposits at the corneal periphery visible by slit-lamp) are present in almost all patients with neurological Wilson disease but absent in up to 50% of hepatic presentations. R

Treatment: penicillamine or trientine (chelators), or zinc (to block absorption via metallothionein induction). Lifelong therapy is required.

CP (Ceruloplasmin / Aceruloplasminemia)

CP encodes ceruloplasmin on chromosome 3q24-q25.

Aceruloplasminemia is an autosomal recessive disorder caused by biallelic loss-of-function mutations in CP.

Common pathogenic variants in Caucasians include homozygosity for Gly631Arg (strongly associated with extrapyramidal symptoms) and Cys338Ser.

The disease manifests in adulthood (ages 45-55 typically), with progressive neurodegeneration, diabetes, retinopathy, and anemia. R

Treatment is primarily chelation therapy (desferrioxamine) to reduce iron accumulation, combined with fresh frozen plasma (which contains functional ceruloplasmin) to transiently restore ferroxidase activity. R

Heterozygous carriers of CP mutations may have mildly reduced ceruloplasmin and mild anemia, without the full aceruloplasminemia phenotype.

SOD1

SOD1 encodes Cu/Zn superoxide dismutase on chromosome 21q22.11.

Gain-of-function mutations in SOD1 cause approximately 20% of familial ALS (amyotrophic lateral sclerosis), through a toxic gain-of-function mechanism distinct from simple loss of dismutase activity.

Common pathogenic variants include A4V (most severe), G93A (most studied in animal models), and E100G.

The precise mechanism by which SOD1 mutations cause motor neuron death involves mitochondrial dysfunction, glutamate excitotoxicity, ER stress, and defects in axonal transport, rather than simply reduced superoxide dismutation.

SLC31A1 (CTR1) And ATP7A

CTR1 (SLC31A1) is the primary copper importer in intestinal cells.

ATP7A (Menkes disease protein) is the copper transporter in the small intestine that exports absorbed copper into portal circulation.

Loss-of-function mutations in ATP7A cause Menkes disease, an X-linked recessive disorder of copper deficiency affecting primarily males.

Menkes disease presents in infancy with neurodegeneration, kinky or steely hair (from impaired lysyl oxidase, reducing keratin crosslinks), hypopigmentation, hypothermia, and severe growth retardation.

Serum copper and ceruloplasmin are extremely low in Menkes disease.

Early treatment with subcutaneous copper histidinate can improve outcomes if started in the neonatal period before irreversible neurological damage occurs.

---

More Research

• Anemia unresponsive to iron therapy in a patient who uses zinc supplements should trigger immediate copper and ceruloplasmin testing before bone marrow biopsy is performed, as the marrow findings of copper deficiency closely mimic MDS and the condition is fully reversible. R
• Ceruloplasmin ferroxidase activity is reduced in the CSF of Parkinson's disease patients and ceruloplasmin protein is reduced in Alzheimer's cortex, suggesting that impaired copper-iron homeostasis through ceruloplasmin may contribute to the iron accumulation seen in both neurodegenerative diseases. R
• For comprehensive trace mineral testing, I use the Nutrient Zoomer (Vibrant Wellness) which includes copper, zinc, ceruloplasmin, magnesium, selenium, vitamins, and amino acids in a single panel.
• High-dose zinc supplementation became markedly more common during and after the COVID-19 pandemic, creating a significant at-risk population for subclinical copper deficiency that may present years after the initial zinc supplementation. Clinicians should ask about zinc supplementation history in any patient with unexplained anemia, neutropenia, or neurological symptoms. R
• Iron therapy will not correct copper deficiency anemia because the anemia of copper deficiency results from impaired ceruloplasmin ferroxidase activity preventing iron mobilization, not from insufficient iron stores. R
• Patients with Roux-en-Y gastric bypass have a 9-10% prevalence of copper deficiency, and copper deficiency myelopathy has been documented years after bariatric procedures in patients who were not receiving copper supplementation. R
• The zinc:copper supplementation ratio should be approximately 10-15:1 (mg zinc to mg copper) when both are being supplemented simultaneously to prevent zinc-induced metallothionein from sequestering dietary copper. R
• Zinc supplementation is a first-line treatment for Wilson disease specifically because it induces the same metallothionein mechanism that causes copper deficiency in supplement users, demonstrating that the clinical effect of zinc on copper absorption is powerful enough to be therapeutic in a disease of copper overload. R